Interventions: CagriSema (Cagrilintide B and Semaglutide I), placebo Primary Outcome Measure: Relative change in body weight Time Frame: From baseline (week 0) to week 80 Study Details Source VK2735 for Weight Management Phase 3 (VANQUISH 1) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes
Content: 60 Capsules 500 mg of Glutathione per capsule plus 275 mg of boosters Enhanced glutathione is clinically proven to be absorbed by the body compared to regular glutathione Glutathione brightens skin by inhibiting the enzyme tyrosinase
Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis
PEA's documented anti-inflammatory, analgesic, antimicrobial, immunomodulatory, and neuroprotective effects make it a versatile ingredient with broad therapeutic applications
